MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

Search

Crinetics Pharmaceuticals Inc

Fechado

SetorSaúde

28.38 -1.22

Visão Geral

Variação de preço das ações

24h

Atual

Mín

28.24

Máximo

29.19

Indicadores-chave

By Trading Economics

Rendimento

-16M

-97M

Vendas

361K

361K

EPS

-1.04

Margem de lucro

-26,807.202

Funcionários

437

EBITDA

-17M

-110M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+162.27% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-467M

2.7B

Abertura anterior

29.6

Fecho anterior

28.38

Sentimento de Notícias

By Acuity

50%

50%

163 / 380 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

1 de jul. de 2025, 23:09 UTC

Ganhos

Constellation Brands 1Q Profit, Sales Decline Amid Softer Consumer Demand -- Update

1 de jul. de 2025, 19:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

1 de jul. de 2025, 23:47 UTC

Conversa de Mercado

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

1 de jul. de 2025, 23:41 UTC

Conversa de Mercado

Gold Steady, Underpinned by U.S. Fiscal-Deficit Concerns -- Market Talk

1 de jul. de 2025, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

James Hardie: Deal Represents Implied Value of $8.4 Billion

1 de jul. de 2025, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

James Hardie: Cash and Stock Deal Implies $54.18 Per AZEK Share

1 de jul. de 2025, 22:21 UTC

Aquisições, Fusões, Aquisições de Empresas

James Hardie Completes Acquisition of AZEK

1 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

1 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

1 de jul. de 2025, 20:24 UTC

Ganhos

Constellation Brands Earnings Miss as Consumers Cool on Alcohol -- Barrons.com

1 de jul. de 2025, 19:55 UTC

Conversa de Mercado

Oil Futures Resume Cautious Rally -- Market Talk

1 de jul. de 2025, 19:27 UTC

Conversa de Mercado

U.S. Natural Gas Futures Lose More Ground -- Market Talk

1 de jul. de 2025, 19:12 UTC

Conversa de Mercado

Dollar Little Changed as Tax-And-Spending Bill Advances -- Market Talk

1 de jul. de 2025, 19:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

1 de jul. de 2025, 18:41 UTC

Aquisições, Fusões, Aquisições de Empresas

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

1 de jul. de 2025, 18:33 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

1 de jul. de 2025, 18:33 UTC

Conversa de Mercado

Gold Gains as Investors Look Ahead on Budget Bill -- Market Talk

1 de jul. de 2025, 18:32 UTC

Conversa de Mercado

Mexico Manufacturing PMIs Remain Weak in June -- Market Talk

1 de jul. de 2025, 18:22 UTC

Conversa de Mercado

Remittances to Mexico Down in May -- Market Talk

1 de jul. de 2025, 17:45 UTC

Conversa de Mercado

Seasonal Demand Supports Further Oil Gains -- Market Talk

1 de jul. de 2025, 17:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Danone Completed Acquisition of Majority Stake in Kate Farms

1 de jul. de 2025, 16:55 UTC

Ganhos

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

1 de jul. de 2025, 16:27 UTC

Conversa de Mercado

Trade Concerns Ease in Bank of Mexico Survey -- Market Talk

1 de jul. de 2025, 16:25 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Home Depot's GMS Buy Unlocks New Vertical Adjacent to SRS -- Market Talk

1 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

1 de jul. de 2025, 15:48 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Home Depot's Offer for GMS Unlikely to Be Beat -- Market Talk

1 de jul. de 2025, 15:46 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

1 de jul. de 2025, 15:46 UTC

Conversa de Mercado

Amazon Seen With Improved Logistics Ahead of Longer Prime Day -- Market Talk

1 de jul. de 2025, 14:54 UTC

Conversa de Mercado

Thales Expected to Stick to This Year's Sales Guidance -- Market Talk

1 de jul. de 2025, 14:49 UTC

Conversa de Mercado

Platinum Prices Extend Rally on China Demand, Supply Worries -- Market Talk

Comparação entre Pares

Variação de preço

Crinetics Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

162.27% parte superior

Previsão para 12 meses

Média 75.43 USD  162.27%

Máximo 97 USD

Mínimo 60 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Crinetics Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

8

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

30.39 / 33.46Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Neutral Evidence

Sentimento

By Acuity

163 / 380 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.